243 related articles for article (PubMed ID: 16125282)
1. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
3. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
4. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
Helguera G; Rodríguez JA; Penichet ML
Mol Cancer Ther; 2006 Apr; 5(4):1029-40. PubMed ID: 16648575
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
6. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
7. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
9. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
Penichet ML; Dela Cruz JS; Shin SU; Morrison SL
Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
[TBL] [Abstract][Full Text] [Related]
10. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
12. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
13. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
16. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
Dela Cruz JS; Lau SY; Ramirez EM; De Giovanni C; Forni G; Morrison SL; Penichet ML
Vaccine; 2003 Mar; 21(13-14):1317-26. PubMed ID: 12615426
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
Peng LS; Penichet ML; Dela Cruz JS; Sampogna SL; Morrison SL
J Interferon Cytokine Res; 2001 Sep; 21(9):709-20. PubMed ID: 11576465
[TBL] [Abstract][Full Text] [Related]
18. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
Nguyen-Hoai T; Baldenhofer G; Ahmed MS; Pham-Duc M; Gries M; Lipp M; Dörken B; Pezzutto A; Westermann J
J Gene Med; 2012 Feb; 14(2):128-37. PubMed ID: 22228591
[TBL] [Abstract][Full Text] [Related]
19. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]